Pinnacle Food Group Develops Breakthrough Process for Recombinant Breast Milk Protein at Hong Kong Lab

Canadian biotech firm Pinnacle Food Group has developed a methanol-free precision fermentation process to manufacture recombinant human lactoferrin cost-effectively at its Hong Kong lab.

Lactoferrin is the darling of the precision fermentation industry, and one company has achieved a technical breakthrough that has lowered production costs for the ingredient.

Based in Vancouver, Pinnacle Food Group has created a methanol-free fermentation process to produce human lactoferrin, a recombinant version of the whey protein found in breast milk.

The Nasdaq-listed firm hit the milestone in its precision fermentation R&D pipeline at its lab in Hong Kong, and says it will significantly reduce costs and tackle bottlenecks to enable high-purity applications for its protein.

Methanol-free process lowers costs and toxicity

Pinnacle Food Group described itself as a biotech company focused on smart agriculture and engineering, driven by a “dual-engine” strategy.

The company combines advanced farming-as-a-service solutions with cutting-edge precision fermentation and synthetic biology platforms to help transition to a highly efficient and sustainable food system.

For its latest breakthrough, its research team developed the first generation of a recombinant yeast strain to produce human lactoferrin using a patented methanol-free fermentation method with Pichia, a yeast genus widely used in the food industry.

For instance, the Komagataella phaffii strain (formerly Pichia pastoris) has an extensive history of safe use in food products, including in alternative proteins such as the heme ingredient in the Impossible Burger. Several other precision fermentation players make use of this fungus too, such as Eden Brew, Cauldron Ferm, and Helaina.

Pinnacle Food Group accesses its Pichia strain via its research collaboration with Canadian company BioBoost Synbio Consulting. Traditional fermentation relies on methanol, a highly flammable, toxic solvent that requires massive capital expenditure and explosion-proof facilities.

Its advanced platform eliminates methanol from the process, mitigating severe fire hazards and substantially reducing operational costs. This also ensures zero toxic residue, a critical advantage for high-purity infant nutrition and pharmaceutical applications, according to the company.

Pinnacle Food Group’s tech validated at pilot scale

Lactoferrin is an iron-binding glycoprotein revered for its gut health and immune-strengthening properties. It’s used to treat low iron levels during pregnancy, to lower the risk of respiratory tract infections, and to promote cell growth. The protein is present in cow’s milk, but at concentrations 10 times lower than in human breast milk.

Unlike its bovine counterpart, bioidentical human lactoferrin can match the structure and function of proteins naturally present in the human body, and is gentler and more effectively absorbed.

The protein has two iron-binding sites, enabling it to bind and transport iron ions – a property that gives it antibacterial and antiviral properties, making it suitable for use in health supplements, infant formula, women’s wellness, functional nutrition, and more.

However, purified lactoferrin is hard to obtain, so its supply is limited and costs are astronomical, ranging from $600 to $2,000 per kg. Precision fermentation enables companies to produce much larger volumes at a cheaper cost.

Pinnacle Food Group says that while human lactoferrin has continued to advance, the underlying methanol-free tech platform has already been successfully validated with other protein targets at pilot scale, demonstrating its readiness for commercial manufacturing.

“This breakthrough marks a critical step forward in our bio-engineering strategy, validating our technical capabilities and accelerating our path toward becoming a premier business-to-business manufacturer and supplier of high-value biological ingredients for our industry partners,” said CEO Jiulong You.

Several companies are working on precision-fermented human lactoferrin, including New York-based Helaina (whose effera ingredient is available in around a dozen products across the US), Australia’s All G (which expects US approval for its recombinant breast milk protein this year), Portugal’s PFx Biotech, and China’s Guoke Xinglian.